Kyoto University Patents Neuroinflammation Suppression Compounds
Summary
The USPTO granted Kyoto University Patent US12605368B2 for pharmaceutical compositions that suppress neuroinflammation. The compositions contain compounds that inhibit DYRK1A protein phosphorylation activity. The patent covers uses for nerve cell protection, neuron precursor cell transplantation assistance, and Nrf2 protein stabilization in glial cells.
What changed
Kyoto University received US Patent US12605368B2 for pharmaceutical compositions containing compounds that inhibit DYRK1A protein phosphorylation activity, effective April 21, 2026. The granted claims cover compositions for suppressing neuroinflammation, assisting neuron precursor cell transplantation, promoting Nrf2 protein stabilization in glial cells, and protecting nerve cells.
Pharmaceutical manufacturers and biotech firms developing neuroinflammation-related therapies should note this patent's scope when designing research programs or navigating freedom-to-operate. The 18 granted claims establish IP protection around DYRK1A inhibition in the neurological context, which could affect licensing discussions or competitive R&D pathways in this therapeutic area.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Suppression of neuroinflammation and composition and method therefor
Grant US12605368B2 Kind: B2 Apr 21, 2026
Assignee
Kyoto University
Inventors
Masatoshi Hagiwara, Akiko Kobayashi
Abstract
A pharmaceutical composition for suppressing neuro-inflammation; a pharmaceutical composition for assisting transplantation of neuron precursor cells, pluripotent stem cells, and/or neurons; a pharmaceutical composition for promoting the stabilization of Nrf2 protein in glial cells; a pharmaceutical composition for protecting nerve cells from neuro-inflammation are provided. Provided is a pharmaceutical composition containing, as an active ingredient, a compound having an inhibiting ability against phosphorylation activity of DYRK1A protein, or a pharmaceutically acceptable salt of the compound.
CPC Classifications
A61K 31/4439 A61K 31/428 A61P 25/00 A61P 25/28 A61P 29/00
Filing Date
2021-03-31
Application No.
17915751
Claims
18
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.